Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3.
Halatsch ME, Kast RE, Karpel-Massler G, Mayer B, Zolk O, Schmitz B, Scheuerle A, Maier L, Bullinger L, Mayer-Steinacker R, Schmidt C, Zeiler K, Elshaer Z, Panther P, Schmelzle B, Hallmen A, Dwucet A, Siegelin MD, Westhoff MA, Beckers K, Bouche G, Heiland T. Halatsch ME, et al. Neurooncol Adv. 2021 Jun 24;3(1):vdab075. doi: 10.1093/noajnl/vdab075. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34377985 Free PMC article.
Erlotinib in glioblastoma: lost in translation?
Karpel-Massler G, Westhoff MA, Kast RE, Wirtz CR, Halatsch ME. Karpel-Massler G, et al. Among authors: halatsch me. Anticancer Agents Med Chem. 2011 Oct;11(8):748-55. doi: 10.2174/187152011797378788. Anticancer Agents Med Chem. 2011. PMID: 21707495 Review.
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Kast RE, Boockvar JA, Brüning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magné N, Marosi C, McDonald K, Muñoz M, Paranjpe A, Pourgholami MH, Sardi I, Sella A, Srivenugopal KS, Tuccori M, Wang W, Wirtz CR, Halatsch ME. Kast RE, et al. Among authors: halatsch me. Oncotarget. 2013 Apr;4(4):502-30. doi: 10.18632/oncotarget.969. Oncotarget. 2013. PMID: 23594434 Free PMC article. Review.
Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells.
Karpel-Massler G, Westhoff MA, Zhou S, Nonnenmacher L, Dwucet A, Kast RE, Bachem MG, Wirtz CR, Debatin KM, Halatsch ME. Karpel-Massler G, et al. Among authors: halatsch me. Mol Cancer Ther. 2013 Sep;12(9):1783-95. doi: 10.1158/1535-7163.MCT-13-0052. Epub 2013 Jul 5. Mol Cancer Ther. 2013. PMID: 23832120
Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma.
Westhoff MA, Zhou S, Nonnenmacher L, Karpel-Massler G, Jennewein C, Schneider M, Halatsch ME, Carragher NO, Baumann B, Krause A, Simmet T, Bachem MG, Wirtz CR, Debatin KM. Westhoff MA, et al. Among authors: halatsch me. Mol Cancer Res. 2013 Dec;11(12):1611-23. doi: 10.1158/1541-7786.MCR-13-0435-T. Epub 2013 Oct 21. Mol Cancer Res. 2013. PMID: 24145173
106 results